Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study

Affiliations

¹ Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy.
² A Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy.
³ Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
⁴ Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
⁵ Section of Dermatology, Department of Medicine, University of Brescia, Brescia, Italy.
⁶ Dermatology Unit, Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
⁷ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

Multicenter Study

Elena Pezzolo et al. J Eur Acad Dermatol Venereol. 2024 Jan.

. 2024 Jan;38(1):e11-e13.

doi: 10.1111/jdv.19382. Epub 2023 Aug 1.

¹ Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy.
² A Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy.
³ Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
⁴ Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
⁵ Section of Dermatology, Department of Medicine, University of Brescia, Brescia, Italy.
⁶ Dermatology Unit, Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
⁷ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

No abstract available

References

1. Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:437-449.
1. Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HCH, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159:596-605. https://doi.org/10.1001/jamadermatol.2023.0627
1. Silverberg JI, Adam DN, Zirwas M, Kalia S, Gutermuth J, Pinter A, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Am J Clin Dermatol. 2022;23:547-559.
1. Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate- to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87:815-824.
1. Pezzolo E, Naldi L. Tralokinumab in the treatment of resistant atopic dermatitis: an open-label, retrospective case series study. J Acad Dermatol Venereol. 2023;37:e644-e645.